Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals

Authors

Gene D. Morse, University at Buffalo, SUNY
Susan Rosenkranz, Harvard University
Michael F. Para, Ohio State University - Main Campus
Yoninah Segal, Harvard University
Robin DiFrancesco, University at Buffalo, SUNYFollow
Elizabeth Adams, Division of AIDS, BethesdaFollow
Barbara Brizz, NIAID
Kevin E. Yarasheski, Washington University School of Medicine in St. Louis
Richard C. Reichman, University of Rochester
ACTG 5043 Protocol Team

Journal

Antimicrobial Agents and Chemotherapy

Publication Date

2005

Volume

49

Issue

8

Inclusive Pages

3373

Document Type

Open Access Publication

DOI

10.1128/AAC.49.8.3373-3381.2005

Rights and Permissions

Morse, G. D., Rosenkranz, S., Para, M. F., Segal, Y., Difrancesco, R., Adams, E., . . . Reichman, R. C. (2005). Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrobial Agents and Chemotherapy, 49(8), 3373-3381. DOI:10.1128/AAC.49.8.3373-3381.2005

Recommended Citation

Morse, Gene D.; Rosenkranz, Susan; Para, Michael F.; Segal, Yoninah; DiFrancesco, Robin; Adams, Elizabeth; Brizz, Barbara; Yarasheski, Kevin E.; Reichman, Richard C.; and ACTG 5043 Protocol Team, "Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals." Antimicrobial Agents and Chemotherapy. 49, 8. 3373. (2005).
https://digitalcommons.wustl.edu/open_access_pubs/2361